Pharvaris N.V.

NASDAQ•PHVS

CEO: Mr. Berndt Axel Edvard Modig CPA, M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-02-05

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

連絡先情報

Emmy Noetherweg 2, Leiden, 2333 BK, Netherlands

31-71-203-6410

pharvaris.com

時価総額

$1.65B

PER (TTM)

-8.3

17.9

配当利回り

52週高値

$29.80

52週安値

$11.51

52週レンジ

76%

順位52Top 73.5%

2.9

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 2.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.70-22.08%

直近4四半期の推移

フリーCF

-$35.87M-8.58%

直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Net Loss Widens Significantly Net Loss reached €134.22M in 2024, a 33% increase, reflecting substantial investment in R&D activities.

Operating Expenses Jump Fifty Percent Total operating expenses increased 50% to €145.69M in 2024, primarily due to €98.56M in R&D spending.

Clinical Data Supports Development Deucrictibant XR prophylaxis showed 84.5% attack rate reduction in Phase 2; Phase 3 trials are now initiated globally.

Cash Position Decreases Cash and equivalents ended 2024 at €280.73M, down 28% from prior year, due to high operating cash usage.

リスク要因

Continued Losses Expected Limited operating history means no revenues; expects to incur losses for several future years before potential profitability.

Funding Needs Remain Substantial Requires substantial additional capital; inability to raise funds on acceptable terms risks delaying programs or insolvency.

Clinical Trial Uncertainty High Clinical setbacks, inconclusive results, or regulatory hurdles could materially affect business and development prospects.

Geopolitical Instability Risks Global events like conflicts in Ukraine and Middle East may disrupt ongoing clinical trials in affected European regions.

見通し

Advance Phase 3 Clinical Trials Continue parallel development of IR (on-demand) and XR (prophylaxis) formulations through global pivotal Phase 3 studies.

Expect Key Phase 3 Readouts Anticipate topline data for RAPIDe-3 (IR) in Q1 2026 and CHAPTER-3 (XR) in the second half of 2026.

Expand Bradykinin Portfolio Leverage expertise to identify new indications beyond HAE, targeting cardiovascular, allergy, and immunology diseases.

Build Integrated Commercial Structure Intends to develop fully integrated sales and marketing organization ahead of potential marketing approval for products.

同業比較

売上高 (TTM)

BCRX

$874.84M

+94.1%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

ATAI

100.0%

+0.0pp

BCRX

97.6%

+1.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
VERA	$2.85B	-8.6	-59.7%	10.5%
WVE	$2.45B	-11.5	-85.0%	2.8%
SYRE	$2.41B	-88.9	-29.4%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月6日

EPS:-$0.71

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし